Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
-
Narrated by:
-
By:
About this listen
Takeaways
- MASH is a significant obesity-related complication.
- Semaglutide shows promise in treating MASH.
- Weight loss is crucial for improving liver health.
- Bariatric surgery remains the most effective treatment.
- The Essence trial indicates a 63% resolution of NASH.
- New medications are being developed for obesity treatment.
- Early intervention is key to preventing severe liver damage.
- Accessibility of medications is a major concern.
- Comparative studies are essential for evaluating new treatments.
- Future treatments may include innovative delivery methods.
Chapters
00:00 Introduction to MASH and Semaglutide Study
04:29 Understanding Metabolic Dysfunction and Its Implications
08:02 Essence Trial: Semaglutide's Impact on MASH
12:58 Comparative Analysis of New Treatments for MASH
17:30 The Future of Obesity Treatment and Drug Accessibility
Join Vineyard - Dr. Spencer's online clinic
See the study
What listeners say about Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.